Vivimed Labs Quarterly Results for Trading Insights
In Mar 2026, Vivimed Labs (VIVIMEDLAB) reported revenue ₹18 Cr and net profit ₹-147 Cr — revenue -40.0% YoY. For annual financials, live price and key ratios, visit VIVIMEDLAB screener.
VIVIMEDLAB Quarterly Results — Revenue, Profit & EPS Highlights
Vivimed Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Vivimed Labs market cap to track the company's total market size over time.
- Revenue of ₹18 Cr in Mar 2026 (-14.3% vs Sept 2025, -40.0% vs Mar 2025)
- Net Profit of ₹-147 Cr in Mar 2026 (-2000.0% vs Sept 2025, -2350.0% vs Mar 2025)
- EBITDA of ₹-135 Cr in Mar 2026 (-13400.0% vs Sept 2025)
- Operating Margin of -1169.0% in Mar 2026 (-1164.0pp vs Sept 2025)
- Earnings Per Share of ₹-17.24 in Mar 2026 (-1859.1% vs Sept 2025)
Vivimed Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIVIMEDLAB quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 18 | 21 | 30 | 22 | 16 | -14.3% | -40.0% |
| Net Profit (₹ Cr) | -147 | -7 | -6 | -6 | -17 | - | - |
| EBITDA (₹ Cr) | -135 | -1 | 2 | 0 | -11 | - | - |
| EPS (₹) | -17.24 | -0.88 | -0.68 | -0.66 | -2.00 | - | - |
| Operating Margin (%) | -1169.0% | -5.0% | -10.0% | -1.0% | -68.0% | - | - |
VIVIMEDLAB Share Price Trend — 1-Year Movement Across Quarterly Results
Vivimed Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse Vivimed Labs ownership structure to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIVIMEDLAB vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vivimed Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹456,449.48 Cr | 1922.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 170.1 |
|
Divis Laboratories
Mar 2026 |
₹225,542.11 Cr | 8744.5 | 2,986 | 751 | -5.0% | - | 25.2% | 308.9 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4932.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 428.5 |
|
Cipla
Mar 2026 |
₹115,699.61 Cr | 1422.0 | 6,612 | 543 | -9.3% | - | 8.2% | 207.0 |
|
Zydus Life Science
Mar 2026 |
₹111,068.11 Cr | 1124.5 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.9 |
All amounts in ₹ Crores